Navigation Links
Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO's Seven Nosologies Program
Date:6/28/2012

NEW YORK, June 28, 2012 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:

Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO's Seven Nosologies Program

http://www.reportlinker.com/p0832795/Pricing-and-Reimbursement-in-Russia---Big-Pharma-Take-Advantage-of-Reimbursement-for-Costly-Drugs-Through-the-DLO's-Seven-Nosologies-Program.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO's Seven Nosologies Program

Summary GBI Research, the leading business intelligence provider, has released its latest research "Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO's Seven Nosologies Program". It provides a comprehensive overview of the healthcare system, and pricing and reimbursement process in Russia, with key data, information and analysis of the steps of the pricing and reimbursement process. The report closely scrutinizes major changes in the pharmaceuticals-related pricing and reimbursement in Russia due to the implementation of a new law "On Circulation of Drugs".

The scenario of pricing and reimbursement of drugs in Russia is in a dynamic phase. The government of Russia increased the funding of National Healthcare Project to improve the primary healthcare provided to Russians. Under the National Healthcare Project, improvement in primary healthcare, out-patient clinics and technology centers was done. The launch of the DLO (the acronym for Additional Medicines Supply Program) program was done for disabled persons, pensioners and patients in need of specialized medicines. It was estimated by the Ministry of Health and Social Development that 15 million people will be covered under this program. Since the option of opting for money instead of medicine was provided under the program, a greater number of patients opted for the money. Those patients who opted for medicines got a chance to be treated by some of the best medicines available for their respective therapy areas.

The VZN program (acronym for Seven Nosologies Program) was segmented from the DLO. This was because there is a set of people who need specialized medicines which are particularly expensive. The other segment of the DLO program is called the Essential Drug Program (ONLS). Compulsory medical insurance for all Russians was introduced in 1995. Under the medical insurance plan Russians recieve treatment, hospitalization, surgical operation, dental care and other facilities free of charge. However, state medical insurance does not seem to be sufficient for all Russians, so private insurance (voluntary medical insurance) players are also active in the field. The implementation of the new law "on circulation of drugs" resulted in the mandatory registration of prices of drugs listed in the Essential Drug List (EDL) in Russia. This means that the Russian government will now regulate the prices of drugs more uniformly. The decision of the Russian government to boost the domestic pharmaceutical market will lead to the launch of more innovative drugs by domestic pharmaceutical companies. Many major global pharmaceutical companies are initiating and expanding their production capacities in Russia to penetrate further into this market.

Scope - Detailed study of the healthcare scenario in the Russia.

- Analysis of the pricing and reimbursement mechanisms in Russia.

- Key changes that follow from the implementation of new law "on circulation of drugs" in the pricing and reimbursement system.

- Details about government bodies which regulate different processes of pricing and reimbursement in Russia.

- Details about share of major companies in reimbursement program of Russia.

- Insight into various reimbursement programs in Russia.

Reasons to buy - Build an understanding of the pharmaceuticals-related key pricing and reimbursement mechanisms in Russia.

- Optimize your investment through identification and understanding of the changes in the pharmaceutical regulatory mechanism in Russia.

- Knowledge about the regulatory bodies who undertake different processes of price registration.

- Develop effective business strategies related to new drug launches through the analytical insight gained from key trends in pricing and reimbursement scene in Russia.

- Negotiate better with the government agencies to maximize reimbursement on the drugs by understanding the mechanism.

1 Table of Contents1 Table of Contents 31.1 List of Tables 41.2 List of Figures 52 Pricing and Reimbursement in Russia - Introduction 72.1 GBI Research Report Guidance 73 Pricing and Reimbursement in Russia - Overview 83.1 Introduction to Healthcare System in Russia 83.1.1 Comparative Analysis 84 Pricing and Reimbursement in Russia - Overview of Pharmaceutical Market in Russia 144.1 Healthcare System in Russia 144.1.1 Health Indicators in Russia 144.1.2 Private Expenditure on Health 184.1.3 Segmentation of Russian Pharmaceutical Market 204.2 PEST Analysis of Russian Pharmaceutical Market 214.2.1 Political 214.2.2 Economical 214.2.3 Social 214.2.4 Technological 224.3 Drug Expenditure 224.3.1 Drug Expenditure as Percentage of Healthcare Expenditure 224.4 Russian Pharmaceutical Market Segmented by Therapeutic Area 235 Pricing and Reimbursement in Russia - Drug Pricing in Russia 255.1 Introduction 255.1.1 Drug Price Authorities in Russia 255.1.2 Price Registration in Russia 265.2 Price Setting Procedures 295.2.1 Essential Drugs List (EDL) Pricing 295.2.2 Historical Pricing Procedures 305.2.3 Current Pricing Procedures 305.2.4 Reasons to Change Prevailing Pricing Procedures 315.3 Type of Compensation for EDL Drugs 315.4 Share of Domestic Drugs in EDL 325.4.1 Share of Domestic Drugs in EDL by Sales Value 325.4.2 Share of Domestic Drugs in EDL by Sales Volume 335.5 Share of EDL in Russian Pharmaceutical Market 345.5.1 Share of EDL in Russian Pharmaceutical Market by Sales Value 345.5.2 Share of EDL Drugs in Russian Pharmaceutical Market by Sales Volume 356 Pricing and Reimbursement in Russia - Reimbursement Programs in Russia 366.1 Introduction 366.1.1 DLO - Reimbursement Program of Russia 366.1.2 The Seven Nosologies Program (VZN) 446.1.3 ONLS Program 496.2 Insurance System 507 Pricing and Reimbursement in Russia - Appendix 517.1 Market Definitions 517.2 Abbreviations 517.3 Research Methodology 527.3.1 Healthcare System 527.3.2 Pharmaceutical Regulations 527.3.3 Pricing of Pharmaceutical Drugs 527.3.4 Reimbursement of Pharmaceutical Drugs 537.3.5 Pricing and Reimbursement in Major Therapy Areas 537.4 Contact Us 537.5 Disclaimer 537.6 Sources 53

1.1 List of Tables

Table 1: Pricing and Reimbursement in Russia, Health Expenditure as a Percentage of GDP ($), %, BRIC and The US, 2006-2009 9Table 2: Pricing and Reimbursement in Russia, Estimated Public Health Spending as a percentage of GDP, BRIC vs The US, 2010-2050 10Table 3: Pricing and Reimbursement in Russia, Public Health Expenditure as a Percentage of Total Health Expenditure ($), BRIC and the US, 2006-2009 11Table 4: Pricing and Reimbursement in Russia, Health Expenditure per Capita ($), BRIC Countries, 2006-2009 12Table 5: Pricing and Reimbursement in Russia, Out of Pocket Health Expenditure as a Percentage of Private Expenditure on Health, BRIC, The US, 2006-2009 13Table 6: Pricing and Reimbursement in Russia, Health Indicators, Russia, 2009 14Table 7: Pricing and Reimbursement in Russia, Share of Domestic and Imported Drugs, Sales Value, %, Russia, 2009 and 2010 15Table 8: Pricing and Reimbursement in Russia, Share of Domestic and Imported Drugs, Sales Volume, %, Russia, 2009 and 2010 15Table 9: Pricing and Reimbursement in Russia, Share of Prescription and OTC Drugs, Sales Value, %, Russia, 2009 and 2010 16Table 10: Pricing and Reimbursement in Russia, Share of Prescription and OTC Drugs, Sales Volume, %, Russia, 2009 and 2010 17Table 11: Pricing and Reimbursement in Russia, Private Expenditure on Health as a Percentage of Total Healthcare Expenditure, Russia, 2000-2009 18Table 12: Pricing and Reimbursement in Russia, Total Expenditure on Health per Capita at Exchange Rate, ($), Russia, 2000-2009 19Table 13: Pricing and Reimbursement in Russia, Pharmaceutical Market Segmentation, Sales Value, %, Russia, 2009-2010 20Table 14: Pricing and Reimbursement in Russia, Segmentation of Out of Pocket Drug Market by Price of Drugs, %, Russia, 2009-2010 22Table 15: Pricing and Reimbursement in Russia, Russian Pharmaceutical Market, Therapy Area, Sales Value, %, 2009-2010 23Table 16: Pricing and Reimbursement in Russia, Russian Pharmaceutical Market, Therapy Area, Sales Volume, %, 2009-2010 24Table 17: Pricing and Reimbursement in Russia, Share of Domestic Drugs in EDL, Sales Value, %, Russia, 2009-2010 32Table 18: Pricing and Reimbursement in Russia, Share of Domestic Drugs in EDL, Sales Volume, %, Russia, 2009-2010 33Table 19: Pricing and Reimbursement in Russia, Share of EDL in Total Russian Pharmaceutical Market, Sales Value, %, Russia, 2009-2010 34Table 20: Pricing and Reimbursement in Russia, Share of EDL in Total Russian Pharmaceutical Market, Sales Volume, %, Russia, 2009-2010 35Table 21: Pricing and Reimbursement in Russia, Number of DLO Beneficiaries, million, Russia, 2005-2010 36Table 22: Pricing and Reimbursement in Russia, Total Value of DLO Program, Russia, 2007-2010 37Table 23: Pricing and Reimbursement in Russia, Segmentation of DLO Sector Based on Sales Value of Domestic and Imported Drugs, 2009-2010 38Table 24: Pricing and Reimbursement in Russia, Segmentation of DLO Sector Based on Sales Volume of Domestic and Imported Drugs, 2008-2009 39Table 25: Pricing and Reimbursement in Russia, Top 10 Companies in DLO Sector, Sales Value, %, Russia, 2009-2010 40Table 26: Pricing and Reimbursement in Russia, Top 15 Companies in DLO Sector, Sales Value, %, Russia, 2008-2010 41Table 27: Pricing and Reimbursement in Russia, Segmentation of Drugs in DLO Program by Price Range, Sales Value, %, 2009-2010 42Table 28: Pricing and Reimbursement in Russia, Segmentation of DLO Program, Sales Value. %, Russia, 2009-2010 43Table 29: Pricing and Reimbursement in Russia, Share of Nosologies in Seven Nosologies Program, Russia, (%), 2008-2009 45Table 30: Pricing and Reimbursement in Russia, Share of Drugs in Seven Nosologies Program, %, 2009-2010 46Table 31: Pricing and Reimbursement in Russia, Share of Drugs in Seven Nosologies Program, %, Russia, 2008-2009 47Table 32: Pricing and Reimbursement in Russia, Segmentation of Drugs in VZN Program by Price Range, Sales Value, %, 2009-2010 48Table 33: Pricing and Reimbursement in Russia, Price Segmentation of Drugs in ONLS Program, Sales Value, %, Russia, 2009-2010 49Table 34: Pricing and Reimbursement in Russia, Private Insurance as a Percentage of Private Healthcare Expenditure, 2000-2009 50

1.2 List of Figures

Figure 1: Pricing and Reimbursement in Russia, Health Expenditure as a Percentage of GDP ($), %, BRIC and The US, 2006–2009 8Figure 2: Pricing and Reimbursement in Russia, Estimated Public Health Spending as a Percentage of GDP, BRIC vs The US, 2010–2050 10Figure 3: Pricing and Reimbursement in Russia, Public Health Expenditure as a Percentage of Total Health Expenditure ($), BRIC and the US, 2006–2009 11Figure 4: Pricing and Reimbursement in Russia, Health Expenditure per Capita ($), BRIC Countries, 2006–2009 12Figure 5: Pricing and Reimbursement in Russia, Out of Pocket Health Expenditure as a Percentage of Private Expenditure on Health, BRIC, The US, 2006–2009 13Figure 6: Pricing and Reimbursement in Russia, Share of Domestic and Imported Drugs, Sales Value, %, Russia, 2009 and 2010 14Figure 7: Pricing and Reimbursement in Russia, Share of Domestic and Imported Drugs, Sales Volume, %, Russia, 2009 and 2010 15Figure 8: Pricing and Reimbursement in Russia, Share of Prescription and OTC Drugs, Sales Value, %, Russia, 2009 and 2010 16Figure 9: Pricing and Reimbursement in Russia, Share of Prescription and OTC Drugs, Sales Volume, %, Russia, 2009 and 2010 17Figure 10: Pricing and Reimbursement in Russia, Private Expenditure on Health as a Percentage of Total Healthcare Expenditure, Russia, 2000–2009 18Figure 11: Pricing and Reimbursement in Russia, Total Expenditure on Health per Capita at Exchange Rate, ($), Russia, 2000–2009 19Figure 12: Pricing and Reimbursement in Russia, Pharmaceutical Market Segmentation, Sales Value, %, Russia, 2009–2010 20Figure 13: Pricing and Reimbursement in Russia, PEST Analysis of Russian Pharmaceutical Market, 2011 21Figure 14: Pricing and Reimbursement in Russia, Segmentation of Out of Pocket Drug Market by Price of Drugs, %, Russia, 2009–2010 22Figure 15: Pricing and Reimbursement in Russia, Russian Pharmaceutical Market, Therapy Area, Sales Value, %, 2009–2010 23Figure 16: Pricing and Reimbursement in Russia, Russian Pharmaceutical Market, Therapy Area, Sales Volume, %, 2009–2010 24Figure 17: Pricing and Reimbursement in Russia, Steps for Entering Pricing and Reimbursement, Russia, 2009 26Figure 18: Pricing and Reimbursement in Russia, Steps for EDL Formation, Russia, 2009 27Figure 19: Pricing and Reimbursement in Russia, Steps for Price Registration, Russia, 2009 27Figure 20: Pricing and Reimbursement in Russia, Registration of Maximum Selling Price of Foreign - Manufactured Drugs, Currency of Price Registration, Russia, 2011 28Figure 21: Pricing and Reimbursement in Russia, Types of Compensation for EDL Drugs, Russia, 2011 31Figure 22: Pricing and Reimbursement in Russia, Share of Domestic Drugs in EDL, Sales Value, %, Russia, 2009–2010 32Figure 23: Pricing and Reimbursement in Russia, Share of Domestic Drugs in EDL, Sales Volume, %, Russia, 2009–2010 33Figure 24: Pricing and Reimbursement in Russia, Share of EDL in Total Russian Pharmaceutical Market, Sales Value, %, Russia, 2009–2010 34Figure 25: Pricing and Reimbursement in Russia, Share of EDL in Total Russian Pharmaceutical Market, Sales Volume, %, Russia, 2009–2010 35Figure 26: Pricing and Reimbursement in Russia, Number of DLO Beneficiaries, million, Russia, 2005–2010 36Figure 27: Pricing and Reimbursement in Russia, Total Value of DLO Program, $bn, Russia, 2007–2010 37Figure 28: Pricing and Reimbursement in Russia, Segmentation of DLO Sector Based on Sales Value of Domestic and Imported Drugs, 2009–2010 38Figure 29: Pricing and Reimbursement in Russia, Segmentation of DLO Sector Based on Sales Volume of Domestic and Imported Drugs, 2008–2009 39Figure 30: Pricing and Reimbursement in Russia, Top 10 Companies in DLO Sector, Sales Value, %, Russia, 2009–2010 40Figure 31: Pricing and Reimbursement in Russia, Segmentation of Drugs in DLO Program by Price Range, Sales Value, %, 2009–2010 42Figure 32: Pricing and Reimbursement in Russia, Segmentation of DLO Program, Sales Value. %, Russia, 2009–2010 43Figure 33: Pricing and Reimbursement in Russia, Share of Nosologies in Seven Nosologies Program, Russia, 2008–2009 44Figure 34: Pricing and Reimbursement in Russia, Share of Drugs in Seven Nosologies Program, %, 2009–2010 46Figure 35: Pricing and Reimbursement in Russia, Share of Drugs in Seven Nosologies Program, Russia, 2008–2009 47Figure 36: Pricing and Reimbursement in Russia, Price Segmentation of Drugs in VZN Program, Sales Value, %, 2009–2010 48Figure 37: Pricing and Reimbursement in Russia, Segmentation of Drugs in ONLS Program by Price Range, Sales Value, %, Russia, 2009–2010 49Figure 38: Pricing and Reimbursement in Russia, Private Insurance as a Percentage of Private Healthcare Expenditure, 2000–2009 50

Companies mentioned

To order this report:Drug and Medication Industry: Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO's Seven Nosologies Program

More  

Market Research Report

Check our  

Industry Analysis and Insights

Contact
Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AcelRx Pharmaceuticals Announces Pricing of a $10.0 Million PIPE Financing
2. Elsevier and Russias Skolkovo Foundation Sign Access Agreement to SciVerse Scopus and SciVal Funding
3. Cardium Announces Plans For Commercializaton Of Excellagen® In The Russian Federation
4. BHR Pharma Expands SyNAPSe® Trial into Thailand, China and Russia
5. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
6. 2012 Pharmaceutical Diversification Trends, Egypt & Saudi Arabia Pharmaceutical Markets Analyzed in New Research Reports
7. Pharmaceuticals: Global Industry Almanac, MarketLine
8. Buyer Spend Activity and Procurement Behaviors and Strategies in the Pharmaceutical Industry - 2012-2013 : Survey Intelligence
9. Nature Made Selected As "Top Recommended Health Product" By U.S. News & World Report And Pharmacy Times
10. EvaluatePharma Names Debbie Paul CEO, Americas to Lead Growth in Key Region
11. Prodigy Health Supplier Partners with Stason Pharmaceuticals to Help Relieve U.S. Drug Shortages
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016  Patients in Alabama seeking ... therapy no longer have to travel out of state. ... Urology Centers of Alabama to provide a total ... qualifying patients. Alabama is ... of prostate cancer using many different modalities. They are the ...
(Date:2/5/2016)... 2016 --> ... that the global active pharmaceuticals ingredients (APIs) market stood ... reach US$185.9 bn by 2020. It is expected to ... 2020. The title of the report is "Active Pharmaceutical ... and by Therapeutic Area) - Global Industry Analysis, Size, ...
(Date:2/5/2016)... 2016 Site Profile: --> ... - The Speech Recognition People, announced their latest primary healthcare case ... care, reduce turnaround times and to save the practice money. ... since 2013 Challenge: --> ,- Wirral CCG ... - Six doctors ,- Wirral CCG ,- VoicePower client since 2013 ...
Breaking Medicine Technology:
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Regular gym ... find themselves having to wait longer to access the treadmills. It’s a predictable trend. ... resolutions to lose weight and get in shape by joining gyms, starting new walking ...
(Date:2/5/2016)... ... ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure Dental Health ... in need. The event is scheduled to take place on February 27, 2016 from ... dental care to community members in need. Each patient will be given the opportunity ...
(Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a ... individuals in the event they are experiencing an illness. Migraines are a severe form ... are afflicted with migraines would not wish the pain on their worst enemy, the ...
(Date:2/5/2016)... ... 2016 , ... –This week, Atascadero water heater company First Call Plumbing ... To view the report, click here or see below. , There ... pros and cons, the type chosen is almost entirely up to personal preference. However, ...
(Date:2/4/2016)... ... February 04, 2016 , ... American Addiction Centers ... the start of Project HoldSpace. Through the partnership, the two organizations seek to ... youth between the ages of 13 and 18. Currently focused on Ohio schools, ...
Breaking Medicine News(10 mins):